Coherus Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	42.17	26.39	257.24	211.04	326.55
Revenue Growth (YoY)	59.81%	-89.74%	21.89%	-35.37%	-31.37%
Cost of Revenue	13.81	8.73	158.99	70.08	57.59
Gross Profit	28.36	17.66	98.25	140.96	268.96
Selling, General & Admin	100.6	125.48	192.02	198.48	169.71
Research & Development	108.89	91.83	109.44	199.36	363.11
Total Operating Expenses	209.49	217.32	301.45	397.84	532.82
Operating Income	-181.13	-199.65	-203.2	-256.88	-263.86
Interest Expense	-9	-10.73	-40.54	-32.47	-22.96
Other Non-Operating Income (Expense)	7.01	-5.01	5.47	-2.4	-0.28
Total Non-Operating Income (Expense)	-1.99	-15.74	-35.07	-34.87	-23.24
Pretax Income	-183.12	-215.39	-238.27	-291.75	-287.1
Provision for Income Taxes	-	-	-0.38	-	-
Net Income	519.17	272.41	-237.89	-291.75	-287.1
Earnings From Discontinued Operations	351.15	243.9	-	-	-
Net Income to Common	519.17	272.41	-237.89	-291.75	-287.1
Net Income Growth	90.59%	-	-	-	-
Shares Outstanding (Basic)	117	115	94	78	75
Shares Outstanding (Diluted)	117	115	94	78	75
Shares Change (YoY)	2.26%	21.65%	21.30%	2.89%	-9.63%
EPS (Basic)	1.43	0.25	-2.53	-3.76	-3.81
EPS (Diluted)	1.43	0.25	-2.53	-3.76	-3.81
EPS Growth	472.00%	-	-	-	-
Free Cash Flow	-138.51	-20.44	-174.88	-241.12	-38.72
Free Cash Flow Per Share	-1.18	-0.18	-1.86	-3.11	-0.51
Gross Margin	67.24%	66.93%	38.19%	66.79%	82.36%
Operating Margin	-429.51%	-756.58%	-78.99%	-121.72%	-80.80%
Profit Margin	398.43%	108.03%	-92.48%	-138.24%	-87.92%
FCF Margin	-328.45%	-77.46%	-67.98%	-114.25%	-11.86%
EBITDA	-177.21	-194.38	-199.41	-253.18	-260.4
EBITDA Margin	-420.21%	-736.58%	-77.52%	-119.97%	-79.74%
EBIT	-181.13	-199.65	-203.2	-256.88	-263.86
EBIT Margin	-429.51%	-756.58%	-78.99%	-121.72%	-80.80%
Effective Tax Rate	0.00%	0.00%	0.16%	0.00%	0.00%

Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q